Market Overview

Don't Be Deceived By Lockheed's Recent Performance


Enumerating several risks faced by Lockheed Martin Corporation (NYSE: LMT), Barclays said the current downtick in shares should be treated with skepticism. The firm also lowered its price target, predicating it on a cut to its 2018 earnings per share estimate.

Barclays lowered its price target to $245 from $250, while retaining its Underweight rating on Lockheed Martin.

Rally Unjustified

Analyst Carter Copeland noted that shares of the defense contractor have outperformed the S&P 500 Index in the past 10 months, although they have come off their high. The analyst noted that shares were cheap on FCF counterpoint, which might appeal to investors in the current yield environment.

However, Barclays sees risk in the company overearning on EPS and cash, from pension. The firm expects Lockheed to earn about $20 in earnings per share in 2020, given expectations that there could be a looming adjustment quarter, resetting estimates, and the pension accounting charges in four years.

Risks Galore

Among the risks to the valuation, is non-cash pension contributing one-third to the total earnings per share. This, according to the firm, would require the pension asset performance remaining strong every year. The firm also thinks FCF growth will remain quite low for several years. In the long-term, Barclays believes F-35 revenue concentration could be an overhang. Additionally, the aggressive and unchanging dividend payout policy also poses risk, the firm said.

Barclays is unsure about revisiting its rating, given the higher-than-average leverage, the ongoing pension and margin risk and additional share loss to rivals Raytheon Company (NYSE: RTN) and Northrop Grumman Corporation (NYSE: NOC).

Latest Ratings for LMT

Aug 2019MaintainsEqual-Weight
Jul 2019DowngradesBuyHold
Jul 2019MaintainsNeutral

View More Analyst Ratings for LMT
View the Latest Analyst Ratings

Posted-In: Barclays Carter CopelandAnalyst Color Price Target Analyst Ratings


Related Articles (LMT + NOC)

View Comments and Join the Discussion!

Latest Ratings

FWONAFBN SecuritiesDowngrades
TRVBank of AmericaDowngrades
PSTGCross ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success

U.S. Auto Sales Mostly Down, Car Stocks Mostly Up